AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track

About this update from Avricore Health Inc.

[{"type":"text","content":"AVRICORE HEALTH CORPORATE UPDATE: 2024 record year, UK expansion on track\n\n\n\n VANCOUVER, British Columbia, May 01, 2025 (GLOBE NEWSWIRE) --\n \n AVRICORE HEALTH INC.\n \n (TSXV: AVCR) (the \"\n \n Company\n \n \" or “\n \n Avricore\n \n ”) reports on its year end 2024 and\n \n\n\n In the year ended December 31, 2024 revenue increased by 37% year over year to $4,785,711 and gross profit increased by 56% to $1,880,306.\n \n\n In the three months ended December 31, 2024 revenue increased by 5% year over year to $1,421,076 and gross profit increased by 18% to $589,930.\n \n\n\n “Launching and expanding HealthTab™ in North East London has been a meaningful milestone in our UK strategy and a testament to the vital role pharmacists can play in preventing chronic disease,” said Hector Bremner, CEO of Avricore Health. “By integrating with NHS systems and working alongside leading healthcare partners, we’re delivering the most accurate, scalable and data-driven solution that is improving patient access to care while supporting the sustainability of frontline pharmacy services.”\n \n\n\n Growth Strategy 2025 and Beyond:\n \n\n\n Recently, the Company announced its strategy to grow HealthTab in the United Kingdom — a decision aligned with the region’s robust healthcare market and significant investment in pharmacy-led services.\n \n\n With operations in the Shoppers Drug Mart locations in Canada having concluded as of March 31, 2025, this allows for the redeployment of devices in Canada and the UK. This transition enhances resource efficiency and reduces upfront capital requirements for expanded device deployment.\n \n\n Because the Company expects devices to be redeployed to new locations in Canada and the UK, management estimates that the Company will not require investment in new devices for the next 12 to 18 months. It also expects cash-on-hand, expected future cash inflows from revenues, and cash savings from redeployment of devices estimated to be sufficient to finance working capital for the next 12 to 18 months.\n \n\n\n UK Expansion Gains Momentum\n \n\n\n In response to rising pressures on primary care, the UK government has committed significant funding to expand the role of community pharmacies in chronic disease prevention and management. In 2024, th...

More updates from Avricore Health Inc.